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Abstract
Lentiviral Envelope (Env) antigenic variation and related immune evasion present major hurdles to effective vaccine
development. Centralized Env immunogens that minimize the genetic distance between vaccine proteins and circulating
viral isolates are an area of increasing study in HIV vaccinology. To date, the efficacy of centralized immunogens has not
been evaluated in the context of an animal model that could provide both immunogenicity and protective efficacy data. We
previously reported on a live-attenuated (attenuated) equine infectious anemia (EIAV) virus vaccine, which provides 100%
protection from disease after virulent, homologous, virus challenge. Further, protective efficacy demonstrated a significant,
inverse, linear relationship between EIAV Env divergence and protection from disease when vaccinates were challenged
with viral strains of increasing Env divergence from the vaccine strain Env. Here, we sought to comprehensively examine the
protective efficacy of centralized immunogens in our attenuated vaccine platform. We developed, constructed, and
extensively tested a consensus Env, which in a virulent proviral backbone generated a fully replication-competent
pathogenic virus, and compared this consensus Env to an ancestral Env in our attenuated proviral backbone. A polyvalent
attenuated vaccine was established for comparison to the centralized vaccines. Additionally, an engineered quasispecies
challenge model was created for rigorous assessment of protective efficacy. Twenty-four EIAV-naı¨ve animals were
vaccinated and challenged along with six-control animals six months post-second inoculation. Pre-challenge data indicated
the consensus Env was more broadly immunogenic than the Env of the other attenuated vaccines. However, challenge data
demonstrated a significant increase in protective efficacy of the polyvalent vaccine. These findings reveal, for the first time, a
consensus Env immunogen that generated a fully-functional, replication-competent lentivirus, which when experimentally
evaluated, demonstrated broader immunogenicity that does not equate to higher protective efficacy.
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Introduction
The scientific community has aggressively sought after the
development of a universal HIV vaccine that can prevail over the
extraordinary levels of antigenic diversity in the fight against HIV and
AIDS. The considerable extent of genomic variation found between
isolates and within clades, and to a larger extent within the circulating
recombinant forms, make for an effectual blockade to vaccine
protection. Different strategies of vaccine composition and delivery
have been proposed that are actively and widely being examined. A
majority of these vaccines target the Env protein, as lentiviral antigenic
variation is most pronounced in the viral Env proteins that serve as
initial primary targets for host immune responses [1–5].
Centralized Env immunogens are one of the more promising
contemporary approaches to overcoming HIV antigenic diversity
[1,6]. Centralized sequences attempt to minimize the genetic
distance between vaccine proteins and the circulating isolates that pose
a threat to public health. The centralized genes are generated through
the computational determination of consensus genes (the most
common amino acid at each position), ancestral genes (modelling
ancestral states through phylogenetics), or center of the tree sequences
(phylogenetic determination of a central isolates) [1,4,7,8]. Centralized
genes have been investigated as effective vaccine approaches in the
HIV field both as DNA and/or protein immunogens [6,9–19]. To
date, however, the efficacy of centralized immunogens has not been
fully explored in the context of an attenuated lentiviral vaccine model
that could provide both immunogenicity data as well as protective
efficacy data via virulent challenge in an animal model.
Equine infectious anemia virus (EIAV), a macrophage-tropic
lentivirus, causes a persistent infection and chronic disease in
equids [20]. Infection, transmitted via blood-feeding horse flies,
occurs in three stages: acute, chronic and inapparent. Acute and
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chronic stages are defined by episodes of clinical disease that are
triggered by waves of viremia, and distinguished by fever, anemia,
thrombocytopenia, edema, and various wasting signs. By one year
post-infection animals typically progress to life-long inapparent
carriers, but continue to harbor steady-state levels of viral
replication in monocyte-rich tissue reservoirs [20–22]. Stress or
immune suppression of inapparent carriers can induce increases in
viral replication and potentially a recrudescence of disease [20,23].
Among virulent lentiviruses, EIAV is unique in that, despite
aggressive virus replication and associated rapid antigenic
variation, greater than 90% of infected animals progress from
chronic disease to an inapparent carrier stage, by a strict
immunologic control over virus replication [20]. The EIAV
system hence serves as a unique animal model for the natural
immunologic control of lentiviral replication and disease. Further,
EIAV inapparent carriers have proven to be resistant to
subsequent virus exposure to diverse viral strains, indicating the
development of a high level of prophylactic immunity. Thus, the
EIAV system provides a valuable model for identifying critical
immune correlates of protection and ascertaining the potential for
developing effective prophylactic lentivirus vaccines [24].
While the disease processes for EIAV and HIV have
distinguishing dynamics, key similarities between the two virus
systems make EIAV an extremely valuable tool and model for
AIDS vaccine development [24–26]. EIAV and HIV are
transmitted parenterally and share a macrophage/monocyte
tropism [26,27]. EIAV quasispecies also possess high levels of
antigenic heterogeneity and their Env proteins share architectural
characteristics such as extensive glycosylation and immune decoys
[24,25,28,29]. These features, all of which are critical elements
associated with initial virus exposure, coupled to a very similar
immune maturation process of the EIAV-infected equine to HIV-
infected humans, are fundamental factors relevant to vaccine
efficacy [24,30].
We previously reported serial studies evaluating the efficacy of
an attenuated EIAV proviral vaccine containing a mutation in the
viral S2 accessory gene (EIAVD9) [31–33]. The results of these
studies indicate that horses inoculated with the EIAVD9 viral
vaccine were 100% protected from disease by virulent, albeit
homologous, EIAV challenge. Thus, the EIAV system mirrors
other animal lentivirus vaccine models, which consistently identify
attenuated vaccines as producing the highest level of vaccine
protection. [31–38]. Our latest EIAVD9 data demonstrated the
effects of challenge virus Env sequence variation on vaccine
protection [39–41]. We identified a significant, inverse, linear
correlation between vaccine efficacy and increasing divergence of
the challenge virus Env surface protein, gp90, compared to the
vaccine virus gp90 protein. The study demonstrated that the
100% protection of immunized horses from disease after challenge
by virus with a homologous gp90 (EV0), dropped to approxi-
mately 60% protection when a challenge virus gp90 was 6%
divergent (EV6), and nose-dived to less than 50% protection
against challenge with a gp90 that was 13% (EV13) divergent from
the vaccine strain. Most recently, we demonstrated that the
attenuated vaccine strain progressively evolved during the seven-
month pre-challenge period and that the observed protection from
disease was significantly associated with divergence from the
original vaccine strain, not the overall diversity of the vaccine Env
quasispecies present on the day of challenge (DOC) [39].
Despite numerous studies on the immunogenicity of centralized
Env proteins, use of these noteworthy immunogens in an
attenuated vaccine model, accompanied by virulent virus
challenge, has yet to be reported. In the current study, we sought
to directly build upon our current model and the series of
described EIAVD9 vaccine studies. Our attenuated vaccine model,
coupled with the well-characterized genomic and phylogenetic
ancestry of the Env gene of our EIAV strain, enabled a thorough,
unparalleled evaluation of centralized sequence vaccine efficacy
not as readily modelled in other lentiviral systems. The presented
studies evaluated multiple derivatives of centralized Env immu-
nogens, both consensus and ancestral, in our proviral attenuated
vaccine backbone. The studies were designed to first, develop and
test a consensus immunogen for functionality through examination
of replication and pathogenic potential in proviral backbones;
second, compare the protective efficacy of the consensus
immunogen in an attenuated backbone to attenuated strains
containing our ancestral Env [34] as well as a polyvalent Env
attenuated strain mixture; and third, to develop and utilize a more
stringent challenge model in the form of an engineered
quasispecies.
Results
Development of consensus Env
Consensus gene development of the EIAV Env protein focused
on the gp90 region of the gene as genomic evolution and antigenic
variation in the transmembrane (gp45) protein has been shown to
be minimal among characterized longitudinal EIAV isolates
[42,43]. To engineer a consensus Env, the gp90 genes of
approximately 90 naturally occurring isolates from an experimen-
tal infection [42,44] were aligned. Virus isolates included the
inoculum strain Env as well as isolates from all three stages of
disease (acute, chronic, and inapparent). Isolates therefore
included an ancestral strain (EV0) and its descendant strains that
evolved innately between day zero and 1200 days post-infection
(DPI). Consensus sequences were derived primarily from codon-
aligned nucleotide sequences and secondarily from amino acid
alignments. The consensus sequence from the nucleotide align-
ment was translated, compared to the consensus sequence from
the amino acid alignment for congruence and the resolution of
ambiguities, and termed ConEnv. To evaluate the veracity of the
derived ConEnv sequence and discriminate it against other
potential consensus Env proteins, additional consensus sequences
were designed. Consensus Envs representing the individual febrile
episodes (six) and inapparent stage isolates were generated from
the isolate amino acid sequences and thereafter a consensus from
Author Summary
Our best effort for containment of the global HIV epidemic
is the development of a broadly protective vaccine.
Current research has focused on vaccines that can
generate a protective immune response against numerous
strains of the virus. For this reason, vaccines with
centralized HIV genes as immunogens, which merge HIV
genetic information and potentially protect against mul-
tiple viral strains in a single inoculation, are an increasing
area of interest to the field. Existing published studies have
not evaluated centralized immunogens in the context of
attenuated vaccines, which to date, have demonstrated
the highest level of vaccine protection in lentiviral studies.
Furthermore, centralized immunogen studies have also
not included protective efficacy findings accomplished
through challenge with highly pathogenic virus strains. In
this study we not only examine the immunogenicity of
these immunogens in an animal model, but we also for the
first time evaluate the ability of centralized immunogens
to induce protection against virulent virus challenge.
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those engineered sequences was constructed as well. This
‘‘consensus from all consensus’’ method is similar to creating
consensus Envs from each HIV clade and subsequently creating a
consensus of those clades. The ConEnv consensus sequence was
then examined by phylogenetic comparison with these control
consensus sequences, the Env sequences involved in ConEnv
construction, and sequences targeted as partner Envs for vaccine
and challenge strains of this study (Fig. 1). The ‘‘consensus from all
consensus’’ sequence was phylogenetically closely related to the
ancestral Env (EV0) emerging on the main ancestral root amongst
the acute disease Env genes. ConEnv shared the same ancestral
root as the EV6 strain, manifesting ancestrally between EV0 and
EV6. Genetic distance calculations demonstrated the ConEnv
gp90 sequence was 4%, 6%, and 11% divergent from the EV0,
EV6, and EV13 strains, respectively. The majority of the disparate
residues occurred within the designated variable regions, specif-
ically V3 through V7 (Fig. 2). Hence, the ConEnv sequence was a
strong consensus sequence representative of the 90 isolates,
capturing epitopes broadly characteristic of the family of EIAV
isolates.
Functional replication assessment and characterization of
the consensus Env
To fully assess the competency of the ConEnv protein to
function indistinguishably from a naturally occurring Env protein,
ConEnv was evaluated in the context of both attenuated and
pathogenic EIAV proviruses. Commercially synthesized ConEnv
was cloned into the attenuated EIAVD9 backbone [31,32] and the
pathogenic EIAVUK3 backbone [45], with the resultant proviral
strains termed ConD9, and EVCon, respectively. Attenuated and
pathogenic proviral clones were sequenced to verify the ConEnv
gene, and then transfected into equine dermal (ED) cells for
production of infectious virus stocks. Virus stocks were titered and
characterized for in vitro replication kinetics [46–48]. Both
proviral strains, EVCon (pathogenic) and ConD9 (attenuated)
demonstrated typical in vitro kinetics, emulating their parental and
variant strain counterparts, and peaked in virus production at
approximately ten DPI.
In vivo analysis of the proviral pathogenic and attenuated
ConEnv strains, by experimental infections of equids, confirmed
characteristic EIAV clinical and virological profiles of both
pathogenic and attenuated infections (Fig. 3). Typical attenuated
and avirulent replication properties were observed for the ConD9
strain. Low level, viral replication kinetics (averaging between 102–
103 copies RNA/ml) which failed to progress to clinical disease
over a 100 day observation period were observed. Conversely,
pathogenesis and virulence, characterized by standard viremic
replication kinetics (averaging between103–104 copies RNA/ml
and peaking at 106 copies RNA/ml), including the induction of
acute, and progression to chronic disease were observed with the
EVCon strain [20,43,49]. Hence, for the first time, a synthetic
consensus lentiviral Env was demonstrated to not only be fully
functional in the context of replication competence in vitro and in
vivo, but also capable of inducing traditional and virulent lentiviral
disease.
The final pre-vaccine trial evaluation was an assessment of
ConEnv’s immunogenicity. Assays of antibody responses elicited
by EVCon, EV0, EV6, and EV13 experimental infections, with
variant and consensus viruses, indicated primarily distinct
neutralization phenotypes for the individual variant Envs; each
variant virus was neutralized by immune serum from homologous
virus infections, but not from heterologous virus infections, except
for marginal neutralization of the EVCon strain by the EV0
heterologous serum (Fig. 4). However, sera produced by the
EVCon virus infections were capable of not only neutralizing its
homologous strain, but also neutralized the EV0 and EV6
heterologous strains. Thus, these data demonstrate that the
ConEnv was similar to EV0, EV6, and EV13 in replication and
virulence properties [34], yet distinct in immune properties as a
result of the defined Env sequence variation. Much like the HIV
consensus Env recombinant proteins that have been reported
[6,15–18], this consensus Env, in the context of a fully functional
virus, demonstrated immunogenicity induction of neutralizing
antibodies with broader recognition of epitopes than that of the
naturally occurring isolates from which the ConEnv was derived.
Experimental vaccination and challenge
To directly evaluate the consensus Env as well as the general
premise of centralized immunogens, we compared the consensus
Env attenuated strain (ConD9) with an ancestral Env attenuated
vaccine strain (EIAVD9 or D9). Proficiency of the centralized
immunogens was further scrutinized by inclusion of a third
attenuated vaccine regimen. The third arm of the study, a
polyvalent attenuated strain mixture, was chosen as the most
rigorous match to the centralized immunogens. The polyvalent
attenuated quasispecies was constructed utilizing the D9 back-
bone. A trivalent attenuated mixture was assembled with the D9 as
one of three strains. The EV6 and EV13 Envs were cloned into
the D9 backbone to create 6D9 and 13D9, respectively, the final
two strains of the polyvalent mix. The polyvalent attenuated
mixture, a 1:1:1 mix of D9, 6D9, and 13D9, otherwise termed
TriD9, was tested in vivo for TCID50 dosage verification in a
group of eight ponies.
Twenty-four ponies of mixed age and gender were divided
randomly into groups of eight animals and inoculated intrave-
nously with two, 36103 TCID50 doses of the ancestral D9 vaccine,
the consensus ConD9 or polyvalent TriD9 vaccines, at four-week
intervals. The inoculated ponies were monitored daily for clinical
signs of EIA, and blood samples were taken at regular intervals for
standard measurements of disease, virus replication, and host
immune responses, as described previously [31–33,50]. Figs. 5–7
display the clinical profiles of vaccinated animals. One of the eight
animals in the polyvalent TriD9 group developed clinical
complications pre-challenge that compromised continued use of
the animal in the study and was thus removed from the trial. All
twenty-three vaccinates (3 trial groups) exhibited no clinical signs
of EIA disease from the attenuated vaccine strains during the
seven month observation period, a time frame that allows
complete maturation of vaccine immunity prior to virus challenge
[22,30,51] (Figs. 5A–7A).
An engineered quasispecies challenge model, EVMX, was
developed as a rigorous assessment of immune protection. Based
on previous studies [28,34], equivalent (1:1:1) TCID50 dosages of
the virulent EV0, EV6, and EV13 strains combined to create the
virulent, well-defined, swarm. Six months following the second
vaccination, the immunized ponies were challenged intravenously
every other day with three, 36103 TCID50, EVMX inoculations. A
control group consisting of six EIAV-naı¨ve ponies was also
challenged with EVMX (Figs. 5B–7B). Analyses of vaccinate day of
challenge (DOC) viral loads demonstrated all three attenuated
viral regimens replicated to similar levels, averaging, over the
seven month pre-challenge period, between 26103 and 36103
copies RNA/ml plasma (Figs. 5–7). Despite these similarities in
viral vaccine replication, however, trial groups displayed markedly
different levels of EVMX-induced disease. Four ancestral D9, six
consensus ConD9, and three polyvalent TriD9 animals displayed
clinical signs of EIA disease during the observation period post
challenge (Figs. 5A–7A). Chronic disease was observed in the
Efficacy of Centralized and Polyvalent Envelope Immunogens
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Fig. 1. Phylogenetic analyses of the ConEnv, all consensus Envs, and the longitudinal isolates derived from experimental infection
utilized in consensus gene development. A phylogenetic tree of aligned plasma amino acid sequences (gp90 regions) was constructed by the
neighbor joining method from Kimura corrected distances with the optimality criterion set to distance. The tree was rooted to the ancestral Env, EV0.
Efficacy of Centralized and Polyvalent Envelope Immunogens
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majority of vaccinates that experienced initial acute disease. All six
control animals of each variant virus challenge group developed
clinical EIA disease, indicating 100% virulence of the quasispecies
challenge under the current experimental infection conditions.
DOC vaccine immune responses in all groups were also indicative
of mature immune responses (Table 1, Table 2, S1 Fig.). The
polyvalent TriD9 group demonstrated the highest Env-specific
serum antibody titer and avidity, although it was only significantly
different from the ancestral D9 regimen (P= 0.017, P,0.0001,
respectively), and not from the consensus ConD9 regimen (S1
Fig.). While neutralizing antibodies were detectable in all three
groups, they could not be associated with protection. Similarly,
DOC cellular immunity levels were similar but not correlated with
protection levels (Table 2). For example, measured in vivo
cytokine responses were the lowest in the polyvalent TriD9
vaccinates that showed the highest level of protection.
The percentage of animals within each trial group protected from
clinical EIA was plotted as a function of days post-challenge for
survival analysis (Fig. 8). Both centralized Env vaccine groups had
subjects that succumbed to EVMX disease within a typical time
frame of 2–3 weeks post-challenge. The polyvalent, TriD9 group,
however, demonstrated a delay in the onset of disease with the first
animal not breaking until 81 days post-challenge (Fig. 8). Overall,
protection curves of all three vaccine groups were significantly
different from one another (ANOVA, P,0.0001). Polyvalent
TriD9 vaccinates demonstrated the highest levels of protection that
was significantly different from the unvaccinated controls and the
consensus ConD9 curves (P,0.0001, P= 0.0002). While the
consensus ConD9 group had the lowest level of protection, it was
significant as compared to unvaccinated subjects (P= 0.001).
Analysis of the trend revealed a significant relationship between
the complexity of immunogen and protective efficacy (P= 0.02).
Ultimately, the consensus ConD9 strain, while pre-trial appearing
to be more broadly immunogenic, demonstrated the lowest level of
protection. The polyvalent TriD9 regimen demonstrated the
highest level of protection against a quasispecies challenge. The
current study not only highlighted important information towards
HIV vaccine development and highlighted the importance of
rigorous challenge strain engineering.
Discussion
The collective success of attenuated vaccine regimens makes it
the ideal modality to rigorously test novel vaccine concepts.
Previous work by our group and others have demonstrated
attenuated vaccines to be an extremely useful tool for vaccine
development, regardless of the potential for marketable advance-
ment of the attenuated platform due to the safety concerns
associated with HIV vaccines. Consequently, we resolved to
examine the efficacy of centralized Env immunogens in our well-
established EIAV attenuated vaccine model. Results presented
here reveal, for the first time, a consensus Env in a fully
replication-competent attenuated virus backbone that can confer
protective efficacy against virulent virus challenge; however, it
does not induce the highest level of protection as compared to
ancestral or polyvalent vaccines.
Bootstrap values were determined over 1000 iterations and are indicated at the nodes of the branches. Branch lengths are proportional to the
distance existing between the sequences.
doi:10.1371/journal.ppat.1004610.g001
Fig. 2. Comparison of deduced amino acid gp90 variable region sequences from EIAV variant Envs (used in attenuated and
challenge strain construction) and ConEnv. The region of env gene coding for the surface glycoprotein, gp90, of the Env variants, EV0, EV6, and
EV13 (ref) was compared to the ConEnv sequence. Deduced amino acid sequences were aligned and compared to EV0 (ancestral Env that is
analogous to the EIAVD9 Env). Only the amino acid residues different from EV0 are reported on the alignment. Dots (?) indicate residues identical to
the EV0 sequence; dashes (-) indicate amino acid deletion; Previously described variable regions V1 through V8 are boxed and shaded in blue.
doi:10.1371/journal.ppat.1004610.g002
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A concept not articulated in most reports on centralized Env
sequences are the specifics involved in the determination of the
consensus sequence. Creation of an ideal consensus sequence
requires careful consideration of various parameters. Our original
attempts to construct a consensus gp90 gene focused on a more
basic approach than what we utilized for the current study. Initial
alignments were performed utilizing the three sequences that
comprise the EVMX quasispecies challenge strain, EV0, EV6, and
EV13 [34]. Phylogenetic analysis of this consensus gp90 demon-
strated that the consensus sequence was located high on the
ancestral root and would not have represented a good consensus
sequence as it was highly related to the ancestral, or EV0 gp90.
Likewise, the ‘‘consensus of all consensus’’ method utilized in both
the HIV and influenza fields [6,9,15,18,19,52–56] resulted in a
gp90 sequence that phylogenetically was more related to early
disease isolates on the ancestral root (Fig. 1) than to the consensus
gene generated from all 90 isolate sequences (nucleotide and
amino acid). In vitro analysis of the virus constructed from the
second-generation consensus gp90, assembled from the 90-isolate
alignment and cloned into a proviral backbone, was found to
infect equine cells, but was not fully replication competent.
Therefore, if we were to analyze this Env in a single-round
infection assay it would falsely appear to be fully functional.
Hence, the 90-isolate sequence alignment was re-evaluated and a
higher level of hand-editing performed, especially in the highly
variable V3 region, prior to consensus generation. This thorough
computational analysis and consideration of the consensus Env
limited the potential sampling bias that obfuscates computational
engineering of protein immunogens [1,57]. Likewise, our use of an
actual ancestoral Env also reduced the potential sampling bias that
is problematic to computationally constructed most recent
common ancestors [1,57]. Additionally, in the absence of
replication analysis and study in an attenuated model, the
incapability of the consensus Env to functional naturally would
not have been observed and a gp90 less representative of a fully
functional Env would have been examined. Ultimately, this is the
Fig. 3. Clinical and virological profiles of ponies inoculated with the consensus Env in attenuated (ConD9) and pathogenic (EVCon)
EIAV viral backbones. EIAV-naı¨ve ponies (8 total) were inoculated intramuscularly with 16103 TCID50 (pink arrow) of EIAV strains containing the
consensus Env in either an (A) attenuated backbone, ConD9, or in (B) our pathogenic backbone, EVCon. Rectal temperature (red line, right Y axis) and
platelet counts (blue dashed line, first left Y axis) were followed daily (X-axis). Quantification of the virus load (green diamond, second left Y axis) was
performed on viral RNA extracted from plasma at periodic time points. Febrile episodes were defined by a combination of two-three features,
including: rectal temperature above 39uC in conjunction with thrombocytopenia (platelet decrease of $70,000/ml of whole blood), EIAV viral load $
105 as well as other clinical signs of EIA.
doi:10.1371/journal.ppat.1004610.g003
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first successful construction of a consensus envelope lentivirus
construct with full replication and virulence properties.
The highest protective efficacy against disease was observed in
the polyvalent TriD9 vaccinates. Survival analysis revealed the
polyvalent TriD9 disease curve was significantly different from the
naı¨ve controls and importantly, the consensus ConD9 curve.
Considering the EVMX challenge quasispecies virus strain
composition, the polyvalent TriD9 regimen displaying the highest
levels of protective efficacy might be anticipated; however, the
ancestral D9 vaccinates also protected to a higher degree than the
consensus ConD9 vaccinates. Pre-challenge analysis of clinical and
virological factors would not have predicted these results. All three
attenuated vaccine regimens displayed similar levels of pre-
challenge viral strain replication. Pre-trial evaluation of the
capability to induce neutralizing antibodies (Fig. 4) indicated that
the ConEnv produced a broader immune response than the
ancestral gp90 (EV0/D9) and also the EV6 and EV13 gp90
proteins. Immune analysis of DOC responses did not reveal a
direct correlation of protection. Neutralizing antibodies and
cellular immune responses were not associated with protective
efficacy. Although a significantly higher level of Env-specific
antibodies were found in the polyvalent TriD9 vaccinates, the
consensus ConD9 vaccinates, similarly, had a higher antibody
response as compared to the ancestral D9. In the case of the
consensus ConD9 vaccinates, immune response data is suggestive
of potential issues related to the artificial nature of the consensus
Env and its ability to induce broadly protective responses.
Protection in all three vaccine groups could be due to anamnestic
responses that could be related to conserved regions or confor-
mational epitopes that allow for protective response in lieu of
sequence identity. Although total antibody binding does not reveal
directly correlative data (S1 Fig.), mapping of the reactive epitopes
will be key to determining if a region of the gp90 potentially
conferred more protective responses. These studies are currently
underway. A notable observation of the polyvalent TriD9
vaccinates was the delayed onset of disease (Fig. 8). The
quasispecies challenge virus eventually broke through causing its
first case of disease at the late time point of 81 days post-challenge.
The nature of this break through is an interesting study of
evolution: did the EVMX Env evolve at a faster rate than the
polyvalent TriD9 and escape the protective immune responses or
did recombination allow the escape. Current studies are being
performed to enable future characterization of break-through
febrile isolates.
As part of the current report we generated an engineered
quasispecies challenge virus mix containing different degrees of
Env variation. The majority of current lentiviral vaccine studies
employ a single strain challenge model. Heterologous challenge
models, while more rigorous than homologous challenge models,
are commonly single viral strains. Data presented here indicate
that more comprehensive challenge models, that include variable
Env proteins, should be developed for the study of lentiviral
Fig. 4. Neutralization profiles of proviral variant strains with serum from animals experimentally infected with EV0, EV6, EV13, or
EVCon. Variant proviral strains were tested for in vivo pathogenecity through experimental infections of ponies. Serum from the infections was
utilized here to test for immunogenicity and characterize the variant Envs. At six-months post-infection serum from two representative animals
(labeled A,B) was tested in our standard neutralization assay. The mean reciprocal dilutions of serum which neutralized 50% of input EV0, EV6, EV13,
or EVCon as measured in an infectious center assay are presented. The dashed line denotes the cut off ($25) value for valid 50% neutralization titers.
doi:10.1371/journal.ppat.1004610.g004
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vaccines to better test the vaccine modalities being investigated.
The polyvalent TriD9 and EVMX vaccine and challenge strains
were at their basic phenotype, a homologous pairing. However,
the complexity of a pathogenic, diverse, challenge strain resulted
in a notable difference and reduction in the protective efficacy as
compared to previous studies where the vaccine and challenge
strains were matched in their Env sequences. Improved challenge
model development for animal lentiviral studies that comprehen-
sively test protective efficacy are critical tools required for broadly
protective vaccine development.
The studies presented here demonstrate definitively that
polyvalent attenuated vaccine regimens have significantly higher
levels of protection as compared to centralized immunogens.
Although it is not possible with absolute confidence to extrapolate
the results of vaccine studies in any single animal lentivirus system
to other animal lentiviruses or to HIV, the data presented here
certainly highlight the priority of ascertaining centralized immu-
nogens on HIV vaccine efficacy in the context of higher animal
models that include challenge studies which can inform on the true
protective nature of the proposed immunogens.
Fig. 5. Clinical and virological profiles of D9 vaccine trial group. (A) Eight EIAV-naı¨ve ponies were vaccinated with 36103 TCID50 D9 I.M.
(orange arrow, Vax). Rectal temperature (red line, right Y axis) and platelet counts (blue dashed line, first left Y axis) were followed daily for up to 320
days (X-axis) after the first vaccine dose. Quantification of the virus load (green diamond, second left Y axis) was performed on viral RNA extracted
from plasma at periodic time points prior to and after virulent virus challenge seven months post-first vaccination with 36103 TCID50 EVMX (1:1:1 -
EV0, EV6, or EV13) I.M (pink arrows, Challenge). (B) Two EIAV-naı¨ve ponies were also challenged with 36103 TCID50 EVMX (1:1:1 - EV0, EV6, or EV13) I.M
(pink arrows, Challenge). Febrile episodes were defined by a achieving a combination of two-three features such as: rectal temperature above 39uC in
conjunction with thrombocytopenia (platelet decrease of $70,000/ml of whole blood), EIAV viral load $105 as well as other clinical signs of EIA.
Burgundy cross symbol, animal euthanized due to severe disease or as endpoint of study.
doi:10.1371/journal.ppat.1004610.g005
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Materials and Methods
Consensus Env and strains
Consensus gp90 Env protein sequence was determined by
alignment of nucleotide (codon alignment) and amino acid
sequences from naturally arisen EIAV isolates originated from
an experimental infection (pony #567) [34,42–44] in the
Geneious Pro package of software (Biomatters, Ltd.). Alignments
were hand edited where necessary, especially in the highly variable
loop region, and ambiguities resolved through partner aligning of
nucleotides and amino acids. Phylogenetic characterization of the
consensus Env was were constructed by the neighbor-joining
method of Jukes Cantor corrected distances with the optimality
criterion set to distance as measured in PAUP [58] and
implemented in the Geneious Pro 5.0.4 (Biomatters Ltd., NZ)
package of software. Statistical significance of branchings and
clustering was assessed by bootstrap resampling of 1000 pseudor-
eplicates on the complete data set; trees were rooted to the original
infectious ancestral Env, EV0. The trees were edited for
publication using FigTree Version 1.1.2. Resultant gp90 sequence
was synthesized (GeneArt, Regensberg, Germany). The consensus
gp90 was cloned into pathogenic and attenuated EIAV backbones
Fig. 6. Clinical and virological profiles of ConD9 vaccine trial group. (A) Eight EIAV-naı¨ve ponies were vaccinated with 36103 TCID50 ConD9
I.M. (orange arrow, Vax). Rectal temperature (red line, right Y axis) and platelet counts (blue dashed line, first left Y axis) were followed daily for up to
320 days (X-axis) after the first vaccine dose. Quantification of the virus load (green diamond, second left Y axis) was performed on viral RNA extracted
from plasma at periodic time points prior to and after virulent virus challenge seven months post-first vaccination with 36103 TCID50 EVMX (1:1:1 -
EV0, EV6, or EV13) I.M (pink arrows, Challenge). (B) Two EIAV-naı¨ve ponies were also challenged with 36103 TCID50 EVMX (1:1:1 - EV0, EV6, or EV13) I.M
(pink arrows, Challenge). Febrile episodes were defined by a achieving a combination of two-three features such as: rectal temperature above 39uC in
conjunction with thrombocytopenia (platelet decrease of $70,000/ml of whole blood), EIAV viral load $105 as well as other clinical signs of EIA.
Burgundy cross symbol, animal euthanized due to severe disease or as endpoint of study.
doi:10.1371/journal.ppat.1004610.g006
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using methods and restriction sites previously described
[34,47,48]. Viral stocks were prepared as previously described
[34,48]. Viral stock titers were determined utilizing our infectious
center assay (cell-based ELISA) in fetal equine kidney cells,
described previously [46].
Experimental infections with ConD9 and EVCon
All equine procedures were conducted in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health at the
Gluck Equine Research Center of the University of Kentucky
according to protocols approved by the University of Kentucky
IACUC (#01058A2006). The animals were monitored daily and
maintained as described previously [31,32,34,43,49]. Eight
outbred, mixed-breed ponies were separated into two groups of
four and experimentally inoculated intravenously with 103
TCID50 of either chimeric strain ConD9 or EVCon. Rectal
temperatures and clinical status were recorded daily. Platelet
numbers were determined using the IDEXX VetAutoread
Hematology Analyzer (IDEXX Laboratories Inc., Westbrook
Fig. 7. Clinical and virological profiles of TriD9 vaccine trial group. (A) Seven of eight EIAV-naı¨ve ponies vaccinated with 36103 TCID50 TriD9
I.M. (orange arrow, Vax) are presented. One of the eight original vaccinates experienced clinical complications and was removed from the trial. Rectal
temperature (red line, right Y axis) and platelet counts (blue dashed line, first left Y axis) were followed daily for up to 320 days (X-axis) after the first
vaccine dose. Quantification of the virus load (green diamond, second left Y axis) was performed on viral RNA extracted from plasma at periodic time
points prior to and after virulent virus challenge seven months post-first vaccination with 36103 TCID50 EVMX (1:1:1 - EV0, EV6, or EV13) I.M (pink
arrows, Challenge). (B) Two EIAV-naı¨ve ponies were also challenged with 36103 TCID50 EVMX (1:1:1 - EV0, EV6, or EV13) I.M (pink arrows, Challenge).
Febrile episodes were defined by a achieving a combination of two-three features such as: rectal temperature above 39uC in conjunction with
thrombocytopenia (platelet decrease of$70,000/ml of whole blood), EIAV viral load$105 as well as other clinical signs of EIA. Burgundy cross symbol,
animal euthanized due to severe disease or as endpoint of study.
doi:10.1371/journal.ppat.1004610.g007
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ME). Clinical EIA (fever) episodes were determined on the basis of
rectal temperature and platelet count (rectal temperature .39uC;
platelet number,100,000/ml of whole blood) in combination with
the viremic presence of infectious plasma virus ($105)
[20,26,43,49,59]. Samples of whole blood, serum, and plasma
were collected weekly as well as daily during fever episodes.
Plasma samples were stored at 280uC until used to determine
plasma viral RNA level.
Challenge strains
The challenge strain EVMX quasispecies was produced by
combining equivalent infectious titers (TCID50) of the variant
challenge strains EV0, EV6, and EV13 [34]. Viral stocks were
prepared as previously described [34,48]. Viral stock titers were
determined utilizing our infectious center assay (cell-based ELISA)
in fetal equine kidney cells, described previously [46].
Experimental subjects, vaccination, and challenge
Equine procedures were conducted at the Gluck Equine
Research Center of the University of Kentucky according to
protocols approved by the University of Kentucky IACUC.
Thirty-six mixed age and gender outbred ponies, serognegative for
EIAV, were utilized. Daily rectal temperatures and clinical status
were recorded. CBC analysis of whole blood was performed using
an IDEXX QBC Vet Autoreader. Hematocrit and platelet
numbers were monitored weekly. The EIAVD9 stock was
produced and vaccinations performed as described [31,34].
Twenty-three vaccinated and six naı¨ve ponies were challenged
with 36103 TCID50 of EVMX. The ponies were monitored daily
for clinical symptoms of EIA, and blood was drawn at regular
intervals (weekly, daily if febrile) for assays of platelets, viral
replication, and virus-specific immune responses. During the
course of these experiments ponies that demonstrated severe
disease-associated symptoms resulting in distress as outlined by the
University of Kentucky IACUC were euthanized.
Quantitative and Qualitative RT-PCR analysis of plasma
virus RNA
Plasma samples from all subjects were analyzed for the levels of
viral RNA per milliliter of plasma using a previously described
quantitative real-time multiplex RT-PCR assay based on gag-
specific amplification primers [60]. The standard RNA curve was
linear in the range of 101 molecules as a lower limit and 108
molecules as an upper limit.
Quantitative assays of cellular immune responses
Our in vivo method for assessing immune reactivity to specific
peptides, described previously [61], was used to explore cellular
immune responses. Forty-four 20-mer peptides, overlapping by
10 residues, spanning the EIAVD9 gp90 were generated (Gen-
Script USA Inc., Piscataway, NJ). An additional 15 peptides,
specific for the variable regions ConD9 gp90, were included in
the pool for analysis of those vaccinates. Vaccinates were
screened for gp90 specific cellular immune responses one week
prior to day of challenge. A 2 mm skin biopsy was collected and
homogenized and RNA extracted. IFNc gene expression was
determined by real-time PCR, as previously described [61].
Amplification efficiencies were determined using Linreg [62] and
samples with amplification efficiencies above 99% were included
for further analyses. Beta-glucuronidase (b-GUS) was used as
housekeeping gene and the DDCT method [63] was used to
determine relative gene expression with saline injection site for
each vaccinate used as the calibrator. Relative quantity (RQ) was
calculated as 22DDCT.
Table 1. Characterization of vaccine Env-specific antibody prior to challenge.*
Trial Group Reciprocal Antibody Titer [10
3] Aviditya Conformationb
PV (EV0, D9) EVCon EV6 EV13 PV (EV0, D9) PV (EV0, D9)
D9 0.62 (60.45) - - - 17 (8) 1.3 (0.37)
ConD9 2.5 (62.7) 1.34 (60.56) - - 33 (12) 1.45 (0.31)
TriD9 3.77 (64.1) - 1.86 (60.62) 1.66 (60.39) 37 (9) 1.12 (0.22)
*Numbers represent averages for each trial group, All values in () are SD.
aAvidity determines the relative resistance of serum antibody;antigen binding to washes with 8M urea in ELISA assays, as described (22).
bConformation ratios reflect the relative serum antibody reactivity to linear or conformational epitopes by comparisons of antibody reactivity with intact and denatured
Env antigens in ELISAs, as described (22); Conformation ratio = denatured Env reactivity/native Env reactivity.
doi:10.1371/journal.ppat.1004610.t001
Table 2. Characterization of vaccine immune responses prior to challenge.*
Trial Group Reciprocal Neutralizing Antibody Titer
a gp90-Specific Cellular Immune Responses, RQb
PV/EV0 EVCon EVMX INFc GrzB CD8 CD4 IL-2
D9 97 (659) - - 76 (620) 3 (60.3) 8 (62) 182 (6116) 4 (61)
ConD9 38 (67) ,25 - 212 (662) 3 (60.4) 4 (61) 7 (62) 6 (62)
TriD9 32 (613) - ,25 6 (62) 1 (60.1) 2 (61) 2 (60.4) 1 (60.4)
*Numbers represent averages for each trial group, All values in () are SD.
aSerum Neutralization titer analyses were against EIAVPV. Positive neutralization determined as reciprocal titers .25 (27, 40).
bPooled responses of all vaccinate-specific peptides; RQ, Relative Quantity, determined as outlined in Materials and Methods.
INFc, Interferon-c; GrzB, Granzyme B.
doi:10.1371/journal.ppat.1004610.t002
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Quantitative and qualitative serological analyses
Serum IgG antibody reactivity to EIAV envelope glycoproteins
was assayed quantitatively (end point titer) and qualitatively
(avidity index, conformation ratio) using our standard concanav-
alin A (ConA) ELISA procedures as described previously [51].
Virus neutralizing activity to the historical reference strain
EIAVPV, and vaccine-specific virus stocks EVCon and EVMX,
mediated by immune sera, was assessed in an indirect cell-ELISA
based infectious center assay using a constant amount of infectious
EIAV and sequential 2-fold dilutions of serum [46,51].
Statistical analyses
Significance of protection from disease was performed by
survival curve analysis as implemented in GraphPad Prism version
6.0d (San Diego, CA). Significance of survival curves were
determined utilizing One-way ANOVA with Bonferroni’s multiple
comparison’s test as well as survival analysis of Kaplan Meier plots
with Logrank test for trend.
Ethics statement
All equine procedures were conducted in accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health at the
Gluck Equine Research Center of the University of Kentucky
according to protocols approved by the University of Kentucky
IACUC (#01058A2006).
Supporting Information
S1 Fig. Day of challenge humoral immune responses in
protected versus unprotected vaccinates. Characterization
of the quantitative and qualitative properties of induced EIAV
envelope-specific humoral responses on the day of challenge were
conducted in ConA serological ELISA assays of serum antibody
(A) endpoint titer, (B) avidity, and (C) conformational dependence;
(D) and 50% serum neutralization titer determinations, all as
described in Materials and Methods. Animals in each vaccinate
group were separated into one of two categories dependent on
their protection or lack of protection from disease. (A) Mean serum
antibody titers are presented as the log10 of the highest reciprocal
dilution yielding reactivity two standard deviations above
background. (B) Mean avidity index measurements are presented
as percentages of the antibody-antigen complexes resistant to
disruption with 8M urea. (C) Mean conformation dependence
values are calculated as the ratio of serum antibody reactivity with
native envelope compared to denatured envelope antigen.
Conformation ratios greater than 1.0 indicate predominant
Fig. 8. Protection from disease is associated with complexity of immunogen. The percentage of animals within each trial group protected
from clinical EIA was plotted as a function of days post-challenge with the engineered quasispecies EVMX. Overall resulting protection curves are
significantly different from one another (ANOVA, P,0.0001). TriD9 demonstrated the highest level of protection (****), followed by D9 (****). The
consensus Env, or ConD9 attenuated vaccine, conferred the lowest level of protection; however, it was significant as compared to unvaccinated
subjects (**). The TriD9 vaccinated animals were also significantly more protected than the ConD9 animals (***). Logrank test for trend via survival
curve analysis reveal a significant trend for the complexity of the immunogen and protective efficacy (P=0.02.) Multiple comparisons performed via
Bonferroni’s multiple comparison test: ****, P,0.0001; ***, P= 0.0002, **, P= 0.001.
doi:10.1371/journal.ppat.1004610.g008
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antibody specificity for conformational determinants, while ratios
less than 1.0 indicate predominant antibody specificity for linear
envelope determinants. (D) The mean reciprocal dilutions of
serum from vaccinated horses, which neutralized 50% of input
EIAVPV, as measured in an infectious center assay. The grey
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